MARINA MATTOS REBEIS
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
- Alopecia areata and novel biologic agents: report of four cases and future directions(2021) GERLERO, Paula; DOCHE, Isabella; REBEIS, Marina; MACEDO, Thalita; RIVITTI-MACHADO, Maria C.
- Evidence for lymphocytic inflammation in non-lesional scalp of folliculitis decalvans: an observational study of 25 patients(2022) DOCHE, I.; HORDINSKY, M. K.; VALENTE, N. S.; SOTTO, M. N.; MIOTTO, I.; REBEIS, M.; RIVITTI-MACHADO, M. C.
- Occipital Fibrosing Alopecia in a Young Male: A Case Report(2021) DOCHE, Isabella; REBEIS, Marina; VALENTE, Neusa; RIVITTI-MACHADO, Maria CeciliaIntroduction: Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia with 3 recognized clinical variants. Lately, LPP clinical spectrum has expanded with new and overlapping clinical variants. First considered as a subtype of LPP affecting postmenopausal women, the increasing worldwide incidence of FFA including atypical lesions in young female and male suggests a different pathomechanism for this disease. Although LPP-spectrum disorders may share similar histopathological findings, clinical features and prognosis are different. Case Report: A 26-year-old Caucasian male presented with occipital scarring alopecia and pruritus for the last 6 months. The patient had been treated for an associated androgenetic alopecia and superficial recurrent scalp folliculitis over the vertex scalp for the last 5 years. Trichoscopy of the occipital scalp showed mild diffuse erythema, moderate peripilar scaling, and absence of follicular openings, suggestive of a scarring process. The patient underwent an occipital scalp biopsy that confirmed the diagnosis of a LPP-spectrum disorder. Discussion/Conclusion: Both LPP and FFA mostly affect the anterior-mid scalp of females. However, recent reports on FFA also in premenopausal women and men should make physicians aware of atypical features of this disease and unusual clinical presentation.
- Clinical features and sex hormone profile in male patients with frontal fibrosing alopecia: A multicenter retrospective study with 33 patients(2022) DOCHE, Isabella; NICO, Marcello M. S.; GERLERO, Paula; REBEIS, Marina; MELO, Daniel F.; TORTELLY, Violeta; RAMOS, Paulo M.; LARRONDO, Jorge; MARDONES, Felipe; GONZALEZ, Martha L.; TOSTI, Antonella; RIVITTI-MACHADO, Maria Cecilia
- Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma(2017) MIYAMOTO, D.; SOTTO, M. N.; OTANI, C. S. V.; FUKUMORI, L. M. I.; PEREIRA, N. V.; SANTI, C. G.; MARUTA, C. W.; BURNIER, M. N. N.; REBEIS, M. M.; AOKI, V.Background Erythroderma is a clinical skin syndrome shared by patients with cutaneous disorders of distinct aetiologies as a result of the combined actions of chemokines, adhesion molecules, and cytokines, such as vascular endothelial growth factor (VEGF). Objective To evaluate the profile of serum levels of VEGF and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) in pemphigus foliaceus (PF) patients with erythroderma. Methods We conducted a retrospective study, which included (i) a chart review of all PF patients from the Autoimmune Blistering Clinic, University of Sao Paulo, Brazil, from January 1991 to December 2014, together with an evaluation of demographic variables, hospitalization duration and complications and (ii) analysis of the circulating VEGF and sVEGFR-1 levels in PF patients with erythroderma by ELISA. The controls included patients with pemphigus vulgaris or psoriasis. Results We observed higher serum VEGF levels in PF patients during erythroderma than during the non-erythrodermic phase. PF patients showed increased serum levels of sVEGFR-1 during the erythrodermic phase in comparison to controls. Interestingly, the sVEGFR-1 and antidesmoglein-1 levels were positively correlated during the non-erythrodermic period. Conclusion Erythroderma, which represents one clinical form of PF, implies more severe outcomes. The circulating levels of VEGF, a potent endothelial activator, are increased in PF patients with erythroderma; this result suggests the contribution of the blood vessel endothelium to the pathogenesis of this clinical syndrome. Interestingly, our findings showed a positive correlation between the sVEGFR-1 and antidesmoglein-1 antibody levels, indicating a suppressive response to VEGF augmentation during the erythrodermic phase of PF.
- Novel blue blotch lesions in folliculitis decalvans - a clinical, histopathological and immunohistochemical study of seven cases(2021) DOCHE, I.; REBEIS, M. M.; GERLERO, P.; VALENTE, N. Y. S.; RIVITTI-MACHADO, M. C.
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital(2022) CEGLIO, William Queiroz Guimaraes Wiegandt; REBEIS, Marina Mattos; SANTANA, Marcela Ferreira; MIYASHIRO, Denis; CURY-MARTINS, Jade; SANCHES, Jose AntonioBackground: Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen. Objective: To evaluate the most common adverse events, as well as the drugs associated with their appearance and the consequences for cancer treatment. Methods: A retrospective study was carried out through the analysis of patients treated at the Clinical Dermatology Unit of a public oncologic hospital. Results: A total of 138 patients with 200 adverse events were evaluated. The most commonly identified adverse events were nail and periungual changes (20%), papulopustular eruptions (13%), acneiform eruptions (12%), hand-foot syndrome (6.5%), hand-foot skin reaction (6%), and xerosis (6%). The most frequently associated antineoplastic treatment groups were classical chemotherapy (46.2%), target therapy (32.3%), and other non-antineoplastic drugs used in neoplasia protocols (16.5%). Of the total number of patients, 17.4% had their treatment suspended or changed due to a dermatological adverse event. Study limitations: Retrospective study and analysis of patients who were referred for specialized dermatological examination only, not allowing the assessment of the actual incidence of adverse events. Conclusion: A wide variety of dermatological manifestations are secondary to antineoplastic treatment with several different drugs resulting, not rarely, in the interruption or modification of therapeutic regimens. (C) 2021 Sociedade Brasileira de Dermatologia.
conferenceObject Increased vascular endothelial growth factor expression in erythrodermic pemphigus foliaceus patients(2016) MIYAMOTO, Denise; OTANI, Camila Sayuri Vicentini; FUKUMORI, Ligia Maria Ichimura; PEREIRA, Naiura Vieira; SOTTO, Mirian Nacagami; MARUTA, Celina Wakisaka; SANTI, Claudia Giuli; REBEIS, Marina Mattos; AOKI, Valeria